Fracture protection in osteoporosis with risedronate

被引：1

作者：

Boonen, S ^{[1
]}

Vanderschueren, D ^{[1
]}

机构：

[1] Katholieke Univ Leuven, Ctr Metab Bone Dis, Louvain, Belgium

来源：

HOSPITAL MEDICINE | 2004年 / 65卷 / 09期

关键词：

D O I：

10.12968/hosp.2004.65.9.15983

中图分类号：

R5 [内科学];

学科分类号：

1002 [临床医学]; 100201 [内科学];

摘要：

Osteoporosis is a major public health problem in the UK, and will become even more common as the population ages. This article will review osteoporosis management and a first-line treatment, risedronate (Actonel), which has been shown to preserve bone quality and reduce the risk of both vertebral and non-vertebral fractures within 6 months of initiation of therapy.

引用

页码：535 / 540

页数：6

共 41 条

[1]

Costs induced by hip fractures:: A prospective controlled study in Belgium [J].

Autier, P ;

Haentjens, P ;

Bentin, J ;

Baillon, JM ;

Grivegnée, AR ;

Colson, MC ;

Boonen, S .

OSTEOPOROSIS INTERNATIONAL, 2000, 11 (05) :373-380

[2]

Bone and Tooth Society of Great Britain National Osteoporosis Society Royal College of Physicians, 2002, GLUC IND OST GUID PR

[3]

Functional outcome and quality of life following hip fracture in elderly women: a prospective controlled study [J].

Boonen, S ;

Autier, P ;

Barette, M ;

Vanderschueren, D ;

Lips, P ;

Haentjens, P .

OSTEOPOROSIS INTERNATIONAL, 2004, 15 (02) :87-94

[4]

Preventing osteoporotic fractures with antiresorptive therapy: implications of microarchitectural changes [J].

Boonen, S ;

Haentjens, P ;

Vandenput, L ;

Vanderschueren, D .

JOURNAL OF INTERNAL MEDICINE, 2004, 255 (01) :1-12

[5]

BOONEN S, 2004, IN PRESS OSTEOPOROUS

[6]

BOONEN S, 2003, CALCIFIED TISSUE INT, V74, P403

[7]

BOONEN S, 2004, IN PRESS J AM GERIAT

[8]

Risedronate preserves bone architecture in postmenopausal women with osteoporosis as measured by three-dimensional microcomputed tomography [J].

Borah, B ;

Dufresne, TE ;

Chmielewski, PA ;

Johnson, TD ;

Chines, A ;

Manhart, MD .

BONE, 2004, 34 (04) :736-746

[9]

BOSE U, 2001, OSTEOPOROUS INT, V12, pS7

[10]

British Medical Association and Royal Pharmaceutical, 2003, BRIT NAT FORM

← 1 2 3 4 5 →